Ataxia With Oculomotor Apraxia Type 2

Watchlist

(log in to enable)

Retrieved

2021-01-18

Source

Gene_reviews

Trials

—

Genes

SETX, APTX, PIK3R5, PNKP, FXN, AFP, MORF4, DDX46, CANT1, DDX19A, SACS, WASF1, ALB, DHX16, XRCC1, TTPA, SPTBN2, POLG, ITPR1, KIF1A, XRCC6P5

Drugs

Ceftriaxone

Interested in hearing about new therapies?

Summary

Clinical characteristics.

Ataxia with oculomotor apraxia type 2 (AOA2) is characterized by onset of ataxia between age three and 30 years after initial normal development, axonal sensorimotor neuropathy, oculomotor apraxia, cerebellar atrophy, and elevated serum concentration of alpha-fetoprotein (AFP).

Diagnosis/testing.

The diagnosis of AOA2 is based on clinical, laboratory, and radiographic features; family history; and exclusion of the diagnosis of ataxia-telangiectasia, AOA1, and AOA4. Identification of biallelic pathogenic variants in SETX by molecular genetic testing confirms the diagnosis.

Management.

Treatment of manifestations: Physical therapy for disabilities resulting from peripheral neuropathy; wheelchair for mobility as needed; educational support (e.g., computer with speech recognition and special keyboard for typing) to compensate for difficulties in reading (caused by oculomotor apraxia) and in writing (caused by upper-limb ataxia).

Preventions of secondary complications: A low-cholesterol diet is advised.

Surveillance: Routine follow up with a neurologist.

Genetic counseling.

AOA2 is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.

Diagnosis

Suggestive Findings

Ataxia with oculomotor apraxia type 2 (AOA2) should be suspected in individuals with the following clinical, laboratory, and radiographic features.

Clinical features

Cerebellar ataxia
Absent or diminished tendon reflexes and later a peripheral axonal sensorimotor neuropathy (>90% of individuals)
Oculomotor apraxia (~51% of individuals)
Pyramidal signs (Plantar response is either flexor or neutral.)
Dystonic posture of the hands, choreic movements, head or postural tremor
Onset between age three and 30 years
Slow progression
Absence of cardiac involvement, cancer predisposition, and immunodeficiency; rare or absent telangiectasia
Absence of severe intellectual disability / cognitive regression
Family history consistent with autosomal recessive inheritance

Laboratory features

Serum alpha-fetoprotein (AFP) concentration >20 ng/mL (normal 0-20 ng/mL) in >95% of affected individuals
Note: Normal serum AFP concentration is highly variable, varies over time, and in individuals with AOA2 is lower than that usually observed in individuals with ataxia-telangiectasia [Mariani et al 2017].
Increased serum total cholesterol concentration >5.6 mmol/L (normal value: 3.5-5.8 mmol/L) in ~50% of affected individuals [Le Ber et al 2004]
Increased serum creatine kinase (CK) concentration in some affected individuals
Elevated immunoglobulin levels (IgG and IgA) reported in several families [Gazulla et al 2010]

Radiographic features. Brain MRI examination shows marked cerebellar atrophy (including cerebellar hemispheres and vermis) with relative sparing of the brain stem.

Other

EMG shows signs of axonal neuropathy in 90%-100% of individuals with AOA2 [Bohlega et al 2011, H'mida-Ben Brahim et al 2011].
Neuropathology. Nerve biopsy confirms axonal neuropathy.
Post-mortem brain examination showed marked loss of Purkinje cells as well as mild fibrous gliosis that was more severe in the vermis than in the hemispheres [Criscuolo et al 2006].

Establishing the Diagnosis

The diagnosis of AOA2 is established in a proband with the above clinical, laboratory, and radiographic features. Identification of biallelic pathogenic variants in SETX by molecular genetic testing (see Table 1) confirms the diagnosis.

Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing, multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing, exome array) depending on the phenotype.

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of AOA2 is broad, individuals with the distinctive features described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those with a phenotype indistinguishable from many other inherited disorders with ataxia are more likely to be diagnosed using genomic testing (see Option 2).

Option 1

When the phenotypic and laboratory findings suggest the diagnosis of AOA2 molecular genetic testing approaches can include single-gene testing or use of a multigene panel:

Single-gene testing. Sequence analysis of SETX detects small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. Perform sequence analysis first. If only one or no pathogenic variant is found, perform gene-targeted deletion/duplication analysis to detect intragenic deletions or duplications (see Table 1).
An ataxia multigene panel that includes SETX and other genes of interest (see Differential Diagnosis) may be considered to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Option 2

When the phenotype is indistinguishable from many other inherited disorders characterized by ataxia, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is the best option. Exome sequencing is most commonly used; genome sequencing is also possible.

Exome array (when clinically available) may be considered if exome sequencing is not diagnostic.

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1.

Molecular Genetic Testing Used in Ataxia with Oculomotor Apraxia Type 2

Gene ¹	Method	Proportion of Pathogenic Variants ² Detectable by Method
SETX	Sequence analysis ³	~80%-92% ⁴
SETX	Gene-targeted deletion/duplication analysis ⁵	~8%-20% ⁶

1.: See Table A. Genes and Databases for chromosome locus and protein.
2.: See Molecular Genetics for information on allelic variants detected in this gene.
3.: Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4.: Moreira et al [2004], Duquette et al [2005], Asaka et al [2006], Criscuolo et al [2006], Fogel & Perlman [2006], Lynch et al [2007], Zühlke et al [2007], Anheim et al [2008], Nicolaou et al [2008], Schöls et al [2008], Anheim et al [2009], Fogel et al [2009], Nakamura et al [2009], Bohlega et al [2011], Hammer et al [2012], Davis et al [2013], Nanetti et al [2013], Roda et al [2014], Newrick et al [2015], Pera et al [2015], Lu et al [2016]
5.: Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
6.: Detailed in Molecular Genetics, Pathogenic variants

Clinical Characteristics

Clinical Description

Ataxia is the first sign of ataxia with oculomotor apraxia type 2 (AOA2) and is the major cause of disability early in the disease course. Later, peripheral sensorimotor neuropathy, particularly of the lower limbs, plays a significant role in disease progression.

Cerebellar ataxia. All affected individuals, after initial normal development, show cerebellar ataxia, with slowly progressive gait imbalance. The first symptoms are recognized between age seven and 25 years (mean 14.6 years) [Anheim et al 2009, Hammer et al 2012]. In a study of ten affected individuals from Italy, age at onset ranged between three and 30 years (mean 20.3 years) [Criscuolo et al 2006].

Neuropathy. Ninety percent to 100% of individuals with AOA2 have sensorimotor neuropathy (i.e., absent or diminished tendon reflexes and sensorimotor deficit).

Oculomotor apraxia. Oculomotor apraxia is present in about 51% of individuals [Anheim et al 2009]. It is characterized by a dissociation of eye-head movements in the "head-free" condition, in which the head reaches the lateral target before the eyes. In an Italian cohort, this feature was present in only 20% of individuals [Criscuolo et al 2006], while in a study of 19 affected Algerian individuals oculomotor apraxia was present in 32% [Tazir et al 2009]. A study of five individuals with AOA2, without head thrusts, revealed that hypometric saccades with a staircase pattern could be a more reliable sign of oculomotor apraxia than head thrust movements [Panouillères et al 2013].

Saccadic pursuit, gaze-evoked nystagmus, poor horizontal optokinetic nystagmus, and square-wave jerks have also been observed in several individuals [Al-Kaabi et al 2011].

In an Algerian study, 37% of affected individuals presented with convergent strabismus [Tazir et al 2009] and in a study of 90 affected individuals worldwide, strabismus was found in 12.3% [Anheim et al 2009]. Unilateral strabismus combined with nystagmus was found in an affected Algerian individual [H'mida-Ben Brahim et al 2011].

Movement disorders. Dystonic posture of the hands, choreic movements, and head or postural tremor are observed in about 14% of individuals [Anheim et al 2009, Tazir et al 2009]. The severity of the movement disorders persists in individuals with AOA2 in contrast to the movement disorder in individuals with ataxia with oculomotor apraxia type 1 (AOA1), in which chorea tends to disappear with time [Le Ber et al 2004]. In the Italian study, extrapyramidal symptoms (including choreiform head movements, truncal dystonia, and head tremor) were reported in 20% of individuals; however, they rapidly disappeared as the disease progressed [Criscuolo et al 2006]. In the French-Canadian group of individuals tremor was an inconsistent feature present in 57% [Duquette et al 2005].

Rarely, involuntary movements have been reported as a prominent presenting sign of AOA2, although they are accompanied by ataxia in almost all individuals. Two individuals had upper limb dystonia as an initial sign. Two sibs presented with prominent chorea of the trunk and face. One individual had isolated head tremor as the initial sign at age nine years [Pearson 2016].

Pyramidal signs were found in 20.5% of individuals with AOA2 [Anheim et al 2009]. Plantar response was either flexor or neutral [Koenig & Moreira 2007]

Intellect. Mild cognitive impairment is present in some individuals [Le Ber et al 2004]; none have had severe intellectual disability or dementia, even after long disease duration [Le Ber et al 2004]. In the Criscuolo et al [2006] study, three of ten persons presented with mild intellectual impairment with onset around age 50 years. A study of the neuropsychological proﬁle of an individual age 45 years with AOA2 indicated that the pathogenesis of the cerebrocerebellar circuit in AOA2 was responsible for the weaker coordination of complex cognitive functions such as working memory, executive functions, speech, and sequence learning [Klivényi et al 2012].

Other. Deep sensory loss [Le Ber et al 2004, Fogel et al 2009, H'mida-Ben Brahim et al 2011], extensor plantar reflexes, swallowing difficulties, and sphincter disturbances are observed in some individuals [Le Ber et al 2004]. Various signs of extraneurologic involvement including early-onset menopause [Criscuolo et al 2006], ovarian failure [Gazulla et al 2009], dermatofibrosarcoma protuberans [Schöls et al 2008], polycystic ovarian syndrome [Fogel et al 2009], and amenorrhea secondary to hypogonadotropic hypogonadism [Anheim et al 2009] have been reported.

Life span. In individuals studied to date, disease duration ranged between two and 53 years, corresponding to the maximum age of last examination, which was at 79 years.

Neuropathology. Chronic axonal neuropathy with preferential loss of large (and to a lesser degree small) myelinated fibers is detected in sural nerve biopsies [Al-Kaabi et al 2011].

Postmortem brain examination in an Italian patient age 79 years who died of heart failure revealed reduction in the overall size of the brain, including atrophy of the cerebellar folia and marked widening of the sulci [Criscuolo et al 2006]. Cerebellar atrophy was most evident at the level of the vermis and the anterior lobe. The brain stem and spinal cord were slightly reduced in size without other anomalies. The substantia nigra appeared normally pigmented. Atheromatous plaques were present in all the arteries of the circle of Willis. Histologic examination showed normal cortical neurons (both in number and shape), marked loss of Purkinje cells in the cerebellar cortex, and mild fibrous gliosis that was more severe in the vermis than in the hemispheres. No inclusions or torpedos were found. The neurons of the dentate nuclei were slightly reduced in number. Chromatolysis of the oculomotor and raphe nuclei was observed in the brain stem. The inferior and accessory olives appeared relatively spared. In the spinal cord severe demyelination of the gracilis and cuneatus funiculi and degeneration of Clarke's columns with gliosis were observed. A study of 3 Tesla (3T) brain MRI examinations of five individuals with AOA2 revealed significant atrophy of all cerebellar lobules. The degree of atrophy was highest in the vermis, consistent with the oculomotor presentation, and the anterior lobe, consistent with kinetic limb ataxia. An absence of hypointensity of the iron signal on susceptibility-weighted imaging (SWI) was seen in the dentate nucleus of all affected individuals [Frismand et al 2013].

Neurochemical patterns. Short-echo, single-voxel proton ((1)H) magnetic resonance spectroscopy performed in nine individuals with AOA2 showed total N-acetylaspartate levels in the cerebellum strongly correlated with the Friedreich Ataxia Rating Scale (FARS), which may be used as a measure of impairment in those with ataxia [Iltis et al 2010].

Genotype-Phenotype Correlations

A study of 90 individuals with AOA2 found that pathogenic missense variants in the helicase domain caused less severe AOA2 phenotypes than missense variants outside of this domain, or deletions, or truncating variants of SETX. However, individuals with pathogenic truncating or missense variants outside of the helicase domain had a lower frequency of pyramidal signs – a finding that may reflect masking of the pyramidal signs by severe motor neuropathy [Anheim et al 2009].

Nomenclature

AOA2 was first known as "ataxia with later onset and high level of alpha-fetoprotein."

Prevalence

The prevalence of p.Leu1976Arg and p.Glu65Lys pathogenic variants was studied by genotyping 154 samples from the Gaspésie region, including 82 French-Canadian and 72 Anglo-Norman control samples [Duquette et al 2005]. In this study, five individuals (3 of Anglo-Norman and 2 of French-Canadian backgrounds) were carriers of the p.Leu1976Arg common French-Canadian variant and none was a carrier of the rarer p.Glu65Lys variant. According to these results, the carrier rate for the p.Leu1976Arg variant is estimated to be 3.5% (1:28) for Québécois of Anglo-Norman origin and 2.1% (1:47) for the French-Canadian population of Gaspésie. No individuals homozygous for the pathogenic variants p.Leu1976Arg or p.Glu65Lys were identified.

A study of 102 individuals with suspected autosomal recessive cerebellar ataxia from Eastern Europe (95 from Alsace, in eastern France) reported seven individuals with AOA2 (6.9%). AOA2 prevalence in Alsace was inferred to be slightly less than 1:400,000 [Anheim et al 2010].

Differential Diagnosis

Childhood. The diagnosis of ataxia with oculomotor apraxia type 2 (AOA2) can be difficult to establish in young children because not all features of the disease are present or apparent. AOA2 in childhood needs to be distinguished from the following disorders:

Ataxia with oculomotor apraxia type 1 (AOA1) is a progressive cerebellar ataxia characterized by childhood onset followed by oculomotor apraxia and a severe primary motor peripheral axonal motor neuropathy. The first manifestation is progressive gait imbalance (mean age of onset: 4.3 years; range: 2-10 years), followed by dysarthria, then upper-limb dysmetria with mild intention tremor. Oculomotor apraxia, usually noticed a few years after the onset of ataxia, progresses to external ophthalmoplegia. All affected individuals have generalized areflexia followed by a peripheral neuropathy and quadriplegia with loss of ambulation about seven to ten years after onset. Hands and feet are short and atrophic. Chorea and upper-limb dystonia are common. Intellect remains normal in some individuals; in others, different degrees of cognitive impairment have been observed. After a long disease duration (>10-15 years), low serum concentration of albumin and high serum concentration of total cholesterol are observed. AOA1 is caused by pathogenic variants in APTX, the gene encoding aprataxin.
Ataxia with oculomotor apraxia type 4 (AOA4) (OMIM 616267) a form of recessive ataxia characterized by mean age at onset of 4.3 years, marked extrapyramidal manifestations, rapid progression, low or normal albumin levels, normal or high cholesterol levels, and elevated alpha-fetoprotein in some individuals. AOA4 is caused by pathogenic variants in PNKP.
When oculomotor apraxia and/or high serum concentrations of alpha-fetoprotein are present, ataxia-telangiectasia (caused by pathogenic variants in ATM) and ataxia-telangiectasia-like disorder (caused by pathogenic variants in MRE11; OMIM 604391) should also be considered.

Adolescence

Friedreich ataxia (FRDA) can be excluded on clinical grounds, as oculomotor apraxia is not observed in FRDA and cerebellar atrophy is not observed on MRI in FRDA early in the disease course. Molecular genetic testing of FRDA can detect pathogenic variants in virtually 100% of affected individuals.
Ataxia with vitamin E deficiency (AVED) and primary coenzyme Q₁₀ deficiency should be considered because they are treatable disorders.

Adulthood. In simplex cases (i.e., a single occurrence in a family), the possibility of spinocerebellar ataxia type 2 (SCA2) (a dominant form of ataxia which also associates cerebellar ataxia with slow eye movements) can be excluded by molecular genetic testing of SCA2.

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with oculomotor apraxia type 2 (AOA2), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:

Neurologic examination including assessment of cranial nerve function, gait and limb ataxia, coordination, tone, strength, reflexes, and sensory perception
Ophthalmologic examination
Physical therapy and occupational therapy assessment of strength and balance
Assessment of cognitive function
Serum cholesterol
Consultation with a clinical geneticist and/or genetic counselor
Serum alpha-fetoprotein (AFP) concentration, if not evaluated previously

Treatment of Manifestations

Physical therapy may be helpful, particularly for disabilities resulting from peripheral neuropathy.

A wheelchair is usually necessary for mobility by age 30 years.

Educational support (e.g., use of a computer with speech recognition and special keyboard for typing) should be provided to compensate for difficulties in reading (caused by oculomotor apraxia) and in writing (caused by upper-limb ataxia).

Prevention of Secondary Complications

A low-cholesterol diet is advised to reduce the risk of adverse health effects of hypercholesterolemia

Surveillance

Routine visits to the attending neurologist are indicated.

Ophthalmologic surveillance is recommended.

Cholesterol level should be monitored regularly.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.